Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC
In May, irpagratinib received Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). It is the first therapeutic agent to utilize molecularly defined biomarkers for precision-targeted treatment of HCC.
The vast majority of patients with advanced HCC treated with current standard-of-care therapies—including immune checkpoint inhibitors (ICIs) and multi-targeted kinase inhibitors (mTKIs)— experience disease progression within one year. Additionally, approximately 30% of HCC patients exhibit FGF19 overexpression, a biomarker associated with more aggressive tumor biology and poorer prognosis. The registrational study of irpagratinib (ABSK-011-205) is a multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of irpagratinib in combination with Best Supportive Care (BSC) versus placebo in combination with BSC, in patients with advanced or unresectable HCC who exhibit FGF19 overexpression and have previously been treated with ICIs and mTKIs. Eligible patients will be randomized in a 2:1 ratio to receive irpagratinib or placebo.
About Irpagratinib (ABSK-011)
Irpagratinib is a highly-selective FGFR4 small molecule inhibitor designed to target overexpression of the FGF19 signaling pathway. Several epidemiological studies indicate that approximately 30% of HCC patients worldwide exhibit FGF19 overexpression. Development of targeted therapies against FGFR4 represent an innovative and novel approach to the treatment of HCC.
To date, no FGFR4 inhibitor has been granted regulatory approval globally. According to Frost & Sullivan, irpagratinib is expected to become the first breakthrough treatment for the treatment of HCC patients with FGF19 overexpression.
In addition to monotherapy, Abbisko Therapeutics is exploring irpagratinib in combination with atezolizumab, an anti-PD-L1 antibody manufactured by F. Hoffmann-La Roche and Roche (China), in a Phase II study. At the previous 2024 ESMO GI Congress, Abbisko presented clinical data demonstrating 220mg irpagratinib BID in combination with atezolizumab achieved a 50% objective response rate (ORR) in FGF19+ HCC patients who had previously received immune checkpoint inhibition therapy.
About Abbisko Therapeutics
Founded in April 2016, Abbisko Therapeutics Co., Ltd. (HKEX: 02256.HK), is an oncology-focused biopharmaceutical company based in Shanghai that is dedicated to the discovery and development of innovative medicines to treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich research & development and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of innovative programs focused on precision oncology and immuno-oncology.
Please visit www.abbisko.com for more information.
View original content:https://www.prnewswire.com/news-releases/abbisko-therapeutics-completes-first-patient-dosing-in-registrational-study-of-irpagratinib-for-hcc-302481972.html
SOURCE Abbisko
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
6 hours ago
- Medscape
Erectile Function After Prostate Radiation: How MRI May Help
TOPLINE: Among patients with prostate cancer who received MRI-guided stereotactic body radiation therapy (SABR), more than 80% demonstrated 'classic' neurovascular bundle patterns and over 96% showed more than 1-cm separation of internal pudendal arteries from the prostate. These findings indicated that most patients have favorable anatomic patterns that would allow radiation oncologists to minimize radiation to structures involved in erectile function and help reduce patients' risk for posttreatment erectile dysfunction. METHODOLOGY: Erectile dysfunction is a common side effect for men with prostate cancer who undergo SABR. Radiation-related damage to critical nearby structures, such as the neurovascular bundles and internal pudendal arteries, likely contributes to this issue. Identifying these structures on MRI during radiation planning can minimize exposure during SABR and reduce the risk for erectile dysfunction. Researchers analyzed 160 consecutive patients with prostate cancer (median age, 70 years) who underwent MRI-linear accelerator-based SABR between January and December 2024. Based on the MRI scans, researchers classified neurovascular bundle patterns into classic (discrete), adherent (dispersed and adherent to the prostatic capsule), or absent. Researchers also measured the shortest distance between internal pudendal arteries to the prostate capsule and the membranous urethral length and compared imaging features by prostate volumes, Prostate Imaging Reporting and Data System (PI-RADS) scores, lesion locations, and Gleason grade group. TAKEAWAY: The classic neurovascular bundle pattern was the most common, present in 80% of right-sided and 85% of left-sided evaluations, while adherent neurovascular bundles were less common, observed in 18.1% of right-sided and 13.8% of left-sided scans. The median shortest distance between internal pudendal arteries and the prostate capsule was 2.3 cm on both sides, with only 3.1% (left side) to 3.8% (right side) of patients having a distance less than 1.0 cm. The median membranous urethral length was 1.5 cm, with only 2.5% of men having one shorter than 1.0 cm. Researchers found no significant association between these MRI features and prostate volumes of greater or less than 40 mL, PI-RADS scores, zonal location of the dominant intraprostatic lesion, and Gleason grade on pathology. IN PRACTICE: 'Most patients with prostate cancer undergoing SABR demonstrated favorable anatomy of the critical structures, potentially important for potency preservation,' the authors wrote, reflecting on the fact that real-time adaptive planning, especially with MRI-guided radiotherapy, has potential for helping 'identify, define, and effectively dose-constrain these critical structures.' SOURCE: The study, led by Sungmin Woo, MD, PhD, NYU Grossman School of Medicine in New York City, was published online in Practical Radiation Oncology. LIMITATIONS: The study was conducted at a single institution, which may limit the generalizability of the findings. Additionally, the analysis excluded patients with prior prostate-directed treatments, artifacts on MRI scans, and extraprostatic extension or those without diagnostic multiparametric MRI scans, restricting applicability to patients with more advanced disease or suboptimal imaging. DISCLOSURES: This study did not receive any specific funding. One author disclosed serving as a consultant for Boston Scientific. The other authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
6 hours ago
- Yahoo
Sanofi stops supply of high cholesterol drug to China due to limited availability
SHANGHAI (Reuters) -Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French pharmaceuticals firm and its partner Regeneron Pharmaceuticals, in China due to limited availability. "The surge in demand has led to limited availability in China, and some other countries," Sanofi said in a statement sent to Reuters, adding "at the moment Praluent's supply in China has already stopped." It didn't say when supply would resume. Sanofi said it had "invested to strengthen global production of Praluent, to meet a rising global demand which accelerated sharply over the past two years". The company said clinical experts had found there were other medicines on China's National Reimbursement Drug List that were "safe and appropriate" for patients currently being treated with Praluent and it was working with healthcare providers in China to "ensure a smooth transition for patients". Sanofi is the latest foreign drugmaker to stop supplying popular medications to China. Merck suspended shipments of its blockbuster human papillomavirus vaccine Gardasil to the country in February, citing weak discretionary spending. Sign in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Japan adopts stricter safety rules after deaths
Japanese boxing officials have voted to implement stricter rules on weight loss and to also introduce urine tests following the deaths of two fighters in Tokyo. Super-featherweight Shigetoshi Kotari, 28, and featherweight Hiromasa Urakawa, also 28, died after sustaining injuries in separate bouts on the same card on 2 August. Both boxers underwent surgery for subdural haematoma - a condition where blood collects between the skull and the brain. Following the event, the Japan Boxing Commission (JBC) announced all Oriental and Pacific Boxing Federation (OPBF) title bouts will now be 10 rounds instead of 12. The Japanese Professional Boxing Association (JPBA), the JBC and gym owners met to discuss the emergency measures on Tuesday. They voted to include urine tests to measure dehydration and agreed that ambulances will be required on site, even for non-world title bouts. Hospitals will partner with the governing bodies to ensure they are equipped to perform emergency surgery for head and other injuries. Fighters will also have to adhere to new rules on how long they must stop sparring during training before a fight. "Officials have decided to take all possible measures to ensure that the deaths of these two boxers are not in vain," Tsuyoshi Yasukochi, secretary general of the JBC, said. Yasukochi said an accident investigation committee will work to find out the cause of the boxers' deaths later in August before updating their guidance on prevention measures. The JBC and JPBA are also scheduled to meet with the organisations' doctors and the amateur boxing federation. Boxing schedule and results 2025 Watch every Born to Brawl episode More boxing from the BBC Notifications, social media and more with BBC Sport
